Natalie Arnold/LinkedIn
Jan 25, 2026, 12:17
Natalie Arnold on 11 Clinical Trials That Will Shape Medicine in 2026
Natalie Arnold, Preventive Cardiologist at University Heart and Vascular Center Hamburg, shared on LinkedIn:
”“What does the coming day hold (for me)?”
(AS Pushkin, Eugene Onegin)
Nature Medicine recently spotlighted 11 clinical trials that may shape medicine in 2026.
Two of them align directly with my research focus in cardiovascular prevention:
• Low-grade inflammation: IL-6 inhibition with ziltivekimab
• Lipoprotein (a): pelacarsen for patients with elevated Lp(a)
2026 may be a key year for turning “residual risk” biology into therapies that improve clinical outcomes.”
Read the full article here.
Article: Eleven clinical trials that will shape medicine in 2026
Author: Mike May
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women
-
Jan 25, 2026, 12:32Dino Mehic on Bleeding Assessment Tools and QoL in BDUC
-
Jan 25, 2026, 12:05Wolfgang Miesbach on GTH Certification Program for Haemophilia Centres in German-Speaking Countries
-
Jan 25, 2026, 11:46Luma Mahairi on What High-Functioning Teams Can Learn From The Blood System
-
Jan 24, 2026, 15:54Nicolas Nesseler on How Common and Serious is Post-Op Bleeding After Heart Transplantation
-
Jan 24, 2026, 15:43Roey Tagansky on Tu Youyou and the Rediscovery That Defeated Malaria
-
Jan 24, 2026, 15:27Mavis Agnes Kisakye on Community Impact at HFU
-
Jan 24, 2026, 15:15Jo Jewell Announces Novartis Foundation and Novo Nordisk Collaboration
-
Jan 24, 2026, 15:02Todd Davenport on The Impacts of Long COVID